Study of acalabrutinib plus venetoclax for relapsed CLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have CLL or SLL that has come back after your first treatment with a BTK inhibitor plus a BCL2 inhibitor (like acalabrutinib or venetoclax) and at least 2 years since that treatment ended.
- You need to have had a good response (partial or complete) to that first treatment.
- Your doctor must have results for certain genetic tests: IGHV status, del(17p), and TP53 mutation.
- You must be able to perform daily activities (ECOG score 0, 1, or 2) and have adequate organ and bone marrow function.
- You cannot have serious heart or blood vessel disease, active bleeding, or conditions like HIV or hepatitis B or C.
- You must not have had another cancer or a major surgery in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well zanubrutinib (a targeted pill) combined with venetoclax (another targeted pill) works for adults with CLL/SLL that came back or progressed after prior treatment. It may help by stopping cancer cells through two different pathways, aiming to shrink disease and improve blood counts.
This Phase 2 study tests venetoclax plus obinutuzumab, and whether adding acalabrutinib (or not) improves outcomes for people with relapsed or refractory CLL/SLL. It aims to see which combination works best and is safe for patients whose leukemia has returned or not responded.
This Phase 2 trial studies whether combining acalabrutinib and venetoclax can shrink or control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or did not respond to prior treatment. It may help by attacking the cancer using two different medicines together.
This trial tests whether acalabrutinib and venetoclax (with or without early obinutuzumab) can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is mainly for people whose disease is high-risk, has come back, or did not respond to earlier treatment.
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
This trial tests whether taking venetoclax on an intermittent schedule (not every day) works as well as taking it continuously when combined with acalabrutinib for people with untreated CLL or SLL. It aims to find a treatment approach that might be just as effective but with fewer side effects.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.